Eye cancer is a rare but serious disease that occurs when abnormal cells begin to grow uncontrollably in or around the eye. It can impact vision, eye function, and, if untreated, can even threaten life.
The history of eye cancer dates back to ancient times, with references found in Greek and Roman medical texts describing unexplained ocular growths. Scientific understanding evolved over the centuries, particularly in the 19th and 20th centuries, when advances in microscopy enabled the classification of eye tumours into benign and malignant types. The introduction of radiation therapy in the mid-20th century marked a major milestone, offering effective treatment for intraocular cancers without requiring complete eye removal.
Today, diagnostic precision has significantly improved with the use of high-resolution imaging and genetic testing. Both children and adults may develop eye cancer, with different types presenting distinct symptoms, risk profiles, and clinical outcomes. Early detection is recognized as the cornerstone of successful treatment, and innovations in targeted therapies and minimally invasive procedures continue to improve prognosis and quality of life.
This think-piece provides a detailed overview of eye cancer, including its definition, early symptoms, and classification by tumour type. It explains the underlying causes, diagnostic protocols, and the full spectrum of treatment options, such as radiation therapy, surgery, laser therapy, chemotherapy, and immunotherapy. Additionally, it also shares where to seek treatment, outlines survival statistics, addresses what to do if eye cancer is suspected, and clarifies how common the condition is across age groups and populations.
The goal of this article is to equip readers with medically accurate, up-to-date information to support early recognition, informed decision-making, and timely access to specialist care for eye cancer.
What is Eye Cancer?
Eye cancer refers to the abnormal, uncontrolled growth of cells in or around the eye. This disease disrupts the normal structure and function of the eye, potentially affecting vision and overall eye health.
Eye cancer develops when genetic changes cause cells within the eye to multiply uncontrollably, leading to tumour formation. These tumours might be benign (non-cancerous) or malignant (cancerous), with malignant tumours having the potential to invade nearby tissues or spread to other parts of the body.
Primary eye cancers originate within the eye itself, while secondary eye cancers originate elsewhere and then spread to the eye. Different tissues within the eye, such as the retina, uvea, or conjunctiva, serve as starting points for various types of eye cancers.
Early detection is crucial because untreated tumours may result in vision loss, eye pain, or even threaten life if the cancer spreads. Regular eye exams help in identifying suspicious changes at an early stage, increasing the chance of successful treatment and recovery.
What are the Symptoms of Eye Cancer?
Eye cancer symptoms involve disruptions in vision, structural changes in the eye, and abnormal ocular sensations. These manifestations are often caused by tumours located within the eye or surrounding orbital tissues.
The primary symptoms of eye cancer include:
- Visual disturbances, such as blurred vision, partial vision loss, or complete blindness, result from tumour pressure on the retina or optic nerve.
- Bulging of the eyeball (proptosis) caused by intraorbital mass expansion or displacement of ocular structures.
- Flashes of light (photopsia), floaters, or mobile shadows within the field of vision that are commonly linked to retinal irritation or detachment.
- Localized pigmentation, including dark spots on the iris or conjunctiva, may indicate melanocytic proliferation or intraocular melanoma.
- Unexplained eye pain, especially when persistent or worsening, potentially indicates tumour infiltration into surrounding nerves or tissues.
- Redness or chronic swelling, particularly in the absence of trauma or infection, may signify inflammatory responses to tumour growth.
Early-stage eye cancer often remains asymptomatic. However, the appearance of any new ocular abnormality, whether visual, structural, or sensory, should prompt immediate medical evaluation to ensure timely diagnosis and intervention.
What are the Types of Eye Cancer?
The common types of eye cancer are sebaceous cell/squamous cell carcinoma of eyelids, intraocular melanoma, retinoblastoma, lymphoma of the eye, and Ocular surface squamous cell carcinoma. Each type affects a different part of the eye and presents distinct features, risks, and treatment approaches. All of them have been explained one by one below:
1. Sebaceous Cell Carcinoma of the Eyelid
This originates from meibomian glands in the eyelid. It presents as a swelling at the lid margin and is often mistaken for a chalazion. Any mass that recurs after surgery, especially in older age groups, must be investigated for cancer.
2. Intraocular Melanoma (Most Common in Adults)
Intraocular melanoma originates in the uvea, particularly the choroid layer of the eye. This cancer remains rare overall but stands out as the most frequent primary eye cancer in adults.
Melanoma in the eye arises from pigment-producing cells and has the potential to grow aggressively. If not detected early, it threatens both sight and, in some cases, life, due to its capacity to spread beyond the eye.
Early stages often produce few or no symptoms, making regular eye exams particularly important for adults, especially those with risk factors such as light skin or eye colour.
3. Retinoblastoma (Most Common in Children)
Retinoblastoma is a genetic cancer that develops in the retina, primarily affecting children under the age of five. This tumour arises when cells in the retina undergo specific genetic changes, most commonly involving the RB1 gene.
Early detection is critical, as this type of cancer responds well to treatment and has a high cure rate. Family members of affected children sometimes carry a genetic predisposition, making genetic counselling valuable for at-risk families.
A classic sign is a white reflection in the pupil (leukocoria), often noticed in photographs, or a crossed eye (strabismus). Rapid diagnosis and prompt therapy lead to excellent outcomes in most cases.
4. Lymphoma of the Eye
Ocular lymphoma typically develops in people with underlying systemic lymphoma or immune system disorders. This cancer involves lymphocytes, a type of white blood cell, and can affect various eye structures, including the conjunctiva and the orbit.
Symptoms may include redness, swelling, or decreased vision, often resembling other inflammatory eye conditions, which complicates diagnosis.
People with compromised immune systems face higher risks, and close monitoring helps with early detection and intervention. Treatment usually involves chemotherapy, radiation, or both, depending on the extent of the disease.
5. Squamous Cell Carcinoma
Squamous cell carcinoma of the eye starts in the surface tissues, such as the conjunctiva.
This form of cancer is less common than melanoma or retinoblastoma but poses significant risks if left untreated.
Chronic sun exposure, older age, and weakened immunity increase susceptibility to this condition. Lesions often appear as raised, reddish patches on the eye surface and require prompt medical evaluation to prevent local invasion or spread.
What are the Causes of Eye Cancer?
Eye cancer develops due to a combination of genetic alterations, environmental exposures, and individual risk factors that initiate uncontrolled cell proliferation within ocular or periocular tissues.
The primary causes and contributing risk factors include:
- Genetic mutations, particularly alterations in the RB1 gene, are directly associated with retinoblastoma and disrupt normal mechanisms of cellular growth and division.
- Ultraviolet (UV) radiation exposure, especially from sunlight or artificial sources such as tanning beds, increases the risk of ocular surface malignancies, including uveal melanoma and squamous cell carcinoma.
- Age and race, with a higher incidence of uveal melanoma observed in older adults and individuals with lighter skin pigmentation, especially those of Caucasian descent.
- Family history of eye cancer or related malignancies, suggesting inherited genetic predispositions that may increase susceptibility to intraocular tumours.
- Immunosuppression, whether due to underlying medical conditions (e.g., HIV/AIDS) or pharmacological treatments (e.g., post-transplant therapies), elevates the risk of developing ocular lymphomas and other secondary cancers.
Although some cases of eye cancer occur without a clearly identifiable cause, the presence of these factors informs both clinical screening protocols and patient education for early detection and risk mitigation.
How is Eye Cancer Diagnosed?
Diagnosis of eye cancer involves a series of specialized tests and clinical evaluations by an ophthalmologist or oncologist.
The process often begins with a thorough eye examination, including a review of symptoms and family history.
Then, advanced imaging techniques such as ultrasound, optical coherence tomography (OCT), and magnetic resonance imaging (MRI) are used to gauge detailed views of internal eye structures and any abnormal growths. These tools help differentiate between benign and malignant lesions, guiding further management.
In some cases, a biopsy, which involves the removal of a small tissue sample, confirms the diagnosis by allowing laboratory analysis of the cells.
Additionally, blood tests and systemic imaging determine whether the cancer has spread beyond the eye, which helps in staging and treatment planning.
How is Eye Cancer Treated?
The treatment of eye cancer involves a combination of therapies tailored to the type, location, and stage of the tumour. Radiation therapy, surgery, laser therapy, chemotherapy, and immunotherapy are the primary modalities used, each chosen based on the specific characteristics of the cancer and the overall health of the patient.
1. Radiation Therapy
Radiation therapy is a targeted treatment modality used to destroy cancerous cells within the eye using high-energy radiation beams. It is frequently employed in cases where surgical removal poses a risk to vision or the structural integrity of the eye. This treatment is especially common for uveal melanoma, which originates deep within ocular tissues and is often not accessible by laser or surgical methods.
There are two primary forms of radiation therapy used in ocular oncology:
- Brachytherapy involves the placement of a small radioactive plaque directly onto the surface of the eye, near the tumour. This localized form of internal radiation delivers a high dose to the tumour while sparing surrounding tissues. It is highly effective for treating medium-sized uveal melanomas and offers the advantage of preserving the eyeball and potentially useful vision.
- External beam radiation therapy (EBRT) uses advanced linear accelerators to direct radiation from outside the body, penetrating through the skin to reach intraocular tumours. Treatment plans are carefully developed by a multidisciplinary team to minimize exposure to critical structures such as the optic nerve, retina, and lens.
Radiation therapy is typically chosen when the tumour is too large or deeply located for laser ablation, or when complete surgical excision would necessitate removal of the entire eye.
It is also preferred in cases involving conjunctival lymphoma or squamous cell carcinoma, especially when the tumour cannot be surgically removed without significant morbidity. In such scenarios, radiation offers effective local tumour control while preserving anatomical structures and, in some cases, functional vision.
The procedure usually takes place in a hospital or specialized centre, and the team includes radiation oncologists and physicists who ensure safety and precision. Patients do not feel the radiation itself, but side effects may develop gradually, depending on the dose and area treated. Common temporary side effects include redness, dryness, irritation, or mild discomfort in the treated eye.
Some people experience longer-term effects, such as cataracts or, less commonly, damage to the retina or optic nerve, which can threaten vision. Regular follow-up is essential to monitor for these complications and address them early if they arise.
Most side effects are manageable with medication or further procedures, and the benefits of controlling the cancer often outweigh the risks, especially when the tumour threatens sight or life.
2. Surgery
Surgery is a major treatment option for eye cancer, especially when the tumour is large, unresponsive to other treatments, or threatens to spread.
The main surgical procedures vary from local resection to enucleation in advanced intraocular malignancy. Let’s understand each surgery option.
- Local resection is preferred for smaller tumours or when preserving vision is possible. This approach removes the tumour along with a small margin of healthy tissue, aiming to save as much of the eye as possible. Local resection requires precise instruments and expertise to avoid damaging vital parts of the eye, such as the retina or optic nerve.
- Excision of only the involved area is ideal for tumours affecting the eyelid, conjunctiva, or surface of the eye. Surgeons carefully reconstruct the eyelid or surface to maintain both appearance and function, sometimes using grafts from other parts of the body.
- Enucleation involves the complete removal of the eye and is reserved for advanced cases, where the cancer occupies much of the eye or vision has already been lost. This procedure immediately eliminates the tumour and prevents the spread of cancer to surrounding structures or distant organs.
Modern surgical techniques have evolved to minimize invasiveness and speed recovery. Microsurgery, guided by operating microscopes and tiny instruments, enables removal of even delicate or deep-seated tumours with less trauma to healthy tissues.
Support from an experienced surgical team, along with counseling and rehabilitation, helps patients adjust to changes in vision or appearance and regain quality of life. Surgery remains a vital tool in the fight against eye cancer and, when indicated, provides hope for long-term survival.
3. Laser Therapy
Laser therapy is a localized treatment modality for eye cancer that employs focused light or heat to destroy small tumours. It is primarily used in early-stage cases, particularly retinoblastoma in pediatric patients, where eye preservation and visual function are clinical priorities.
Laser therapy is administered through two main techniques:
- Laser photocoagulation delivers high-intensity light beams to coagulate blood vessels supplying the tumour. By obstructing the tumour’s vascular supply, this method induces ischemia and subsequent tumour cell death. It is best suited for small, well-localized intraocular tumours that have not extended beyond their primary site.
- Laser thermotherapy uses infrared light to raise the temperature of tumour tissues, leading to thermal destruction of malignant cells. This approach is often combined with chemotherapy, as heat enhances drug absorption at the tumour site, improving overall treatment efficacy.
Laser therapy is minimally invasive, often performed under local anesthesia in an outpatient setting. The precision of laser energy minimizes collateral damage to adjacent healthy tissues, thereby preserving retinal architecture and maximizing the potential for vision retention.
Children with retinoblastoma benefit greatly from laser therapy, as it avoids the risks and side effects of more aggressive treatments like radiation or surgery. Multiple sessions are sometimes required, depending on the size and response of the tumour.
In adults, laser therapy is less commonly used, but it can be effective for certain small melanomas or tumours located on the surface of the eye. The choice depends on the tumour’s size, location, and how well it responds to initial treatment.
Side effects of laser therapy are usually mild and temporary, such as slight discomfort, swelling, or redness in the treated eye. Rarely, laser scars can affect vision, especially if the tumour is close to the centre of the retina.
4. Chemotherapy
Chemotherapy is a treatment for eye cancer that uses powerful drugs to destroy cancer cells or stop them from multiplying.
Chemotherapy can be delivered systemically, meaning the drugs travel throughout the body and reach the eye via the bloodstream. This method is useful when there is suspicion of microscopic spread or when multiple tumours exist in both eyes.
Another technique involves local delivery of chemotherapy, such as intravitreal injection, where drugs are injected directly into the eye. This targets the tumour more precisely, reducing side effects in the rest of the body. Intra-arterial chemotherapy, in which drugs are infused into the artery supplying the eye, is also used for retinoblastoma, maximizing tumour exposure to the medication.
The choice of drugs and method of administration depends on the type of cancer, its location, and the patient’s age and overall health. Chemotherapy is often combined with laser therapy, radiation, or surgery to achieve the best possible outcome, minimizing the risk of recurrence.
5. Immunotherapy
Immunotherapy is an emerging treatment for eye cancer that harnesses the body’s immune system to target and destroy cancer cells. This approach is gaining importance, especially for metastatic or recurrent eye cancers that do not respond well to traditional therapies like surgery or radiation.
Unlike chemotherapy, which attacks all rapidly dividing cells, immunotherapy works by stimulating or enhancing the body’s natural defences to recognize and eliminate cancer. This is achieved through drugs known as immune checkpoint inhibitors, monoclonal antibodies, or therapeutic vaccines.
For eye cancers such as metastatic uveal melanoma or advanced conjunctival melanoma, immunotherapy offers new hope where options were once limited. Drugs like pembrolizumab or nivolumab, which block the PD-1/PD-L1 pathway, are being studied for their ability to boost immune response against tumour cells.
Research is ongoing to determine the best combinations and timing for immunotherapy, as not all eye cancers respond equally. Success depends on factors such as tumour genetics, the surrounding immune environment, and the overall health of the patient.
Immunotherapy is generally given intravenously or by injection, sometimes in combination with other treatments. Side effects differ from those of chemotherapy; most result from an overactive immune response and can include fatigue, skin rash, diarrhea, or inflammation of organs like the lungs or liver.
Doctors provide close monitoring to manage these side effects, adjusting or pausing treatment if necessary. Although immunotherapy does not work for every patient, those who do respond sometimes experience long-lasting remission with fewer long-term side effects.
For patients with metastatic or recurrent eye cancers, immunotherapy represents an important step forward, offering hope of control or even remission when standard treatments have failed.
After treatment, ongoing monitoring and follow-up are essential to detect any recurrence or complications early. Advances in medical technology and a multidisciplinary approach have significantly improved outcomes for people with eye cancer, offering the possibility of both survival and preservation of vision in many cases.
Where to Visit for Eye Cancer Treatment?
Eye cancer treatment should be sought at specialized ophthalmic oncology centres equipped with advanced diagnostic tools, experienced multidisciplinary teams, and access to both conservative and surgical interventions. The choice of facility depends on the type, stage, and location of the tumour, as well as the patient’s age and overall health.
Tertiary eye care hospitals with dedicated oncology departments offer comprehensive services, including:
- High-resolution ocular imaging for early detection.
- Access to therapies such as laser treatment, brachytherapy, chemotherapy, and enucleation when necessary.
- Pediatric oncology services for managing conditions like retinoblastoma.
- Integrated support from oncologists, radiologists, ocular surgeons, and rehabilitation specialists.
In India, centres such as Eye7 Eye Hospitals provide focused care for ocular tumours using protocol-driven treatment plans aligned with global standards. With subspecialists in ocular oncology and access to minimally invasive technologies, such institutions are well-positioned to manage both common and rare forms of eye cancer.
Patients should prioritize hospitals that offer not only treatment but also post-therapy vision rehabilitation, long-term monitoring, and genetic counselling when indicated.
What is the Survival Rate for Eye Cancer?
The survival rate for eye cancer ranges from over 95% for early-treated retinoblastoma in children to around 80% for early-stage uveal melanoma in adults, but drops significantly for metastatic disease. Early detection is the most critical factor affecting outcomes, as both retinoblastoma and uveal melanoma respond far better to treatment before the cancer spreads outside the eye.
For children with retinoblastoma, modern therapies provide a cure in more than 95% of cases when the disease is localized and treated promptly. This remarkable survival rate reflects rapid advances in chemotherapy, laser therapy, and coordinated care at specialized centres.
In adults, uveal melanoma, though less common, shows about an 80% five-year survival rate if caught early. This percentage drops sharply if the cancer spreads, especially to organs like the liver, where survival is much lower and treatment focuses on prolonging life and improving comfort.
Metastatic eye cancers, regardless of the original type, have significantly poorer outcomes. When eye cancer spreads beyond the eye, five-year survival rates can fall below 20%, highlighting the urgency of early intervention and ongoing research for advanced cases.
Other types of eye cancer, such as lymphoma of the eye or squamous cell carcinoma of the conjunctiva, vary in prognosis. Lymphoma survival depends on whether the disease is localized or part of widespread systemic lymphoma, while conjunctival squamous cell carcinoma has a better outlook if treated before it invades deeper tissues.
Regular follow-up is essential because even after successful treatment, recurrence is possible. Lifelong monitoring, including eye exams and imaging, helps detect new or returning tumours early, further improving survival odds.
Is Eye Cancer Curable?
Eye cancer is often curable in the early stages when the disease remains contained within the eye. Localized tumours often respond well to targeted treatments such as plaque radiotherapy, laser photocoagulation, or surgical excision. The possibility of a cure diminishes significantly once the cancer spreads outside the ocular tissues.
In clinical practice, patients who remain in complete remission for five years or more are sometimes considered “cured,” though ongoing surveillance is generally advised because recurrence, though uncommon, remains possible.
Among eye cancers, retinoblastoma (the most common eye cancer in children) has excellent survival rates when treated early using chemotherapy and focal therapies.
Relative survival data from the United States (SEER database) from 2015-2021 support these observations:
- For ocular melanoma confined to the eye (localized stage), the 5‑year relative survival rate is approximately 88%.
- If the cancer has spread beyond the eye (distant metastasis), the 5‑year survival rate falls to around 16%.
Thus, while not all eye cancers are curable, many cases, especially those diagnosed early, can be treated successfully, and some patients may achieve long-term remission indistinguishable from “cure” in practical terms. Regular eye checkups are essential to detect recurrence or late complications.
What to Do if You Suspect Eye Cancer?
If you suspect you have eye cancer, seek immediate evaluation from an ophthalmologist or ocular oncologist. A professional will perform a comprehensive eye examination and evaluate both benign and malignant eye conditions.
If you experience persistent symptoms (vision changes, blurred vision, floaters, flashes of light, or visible eye discolouration, dark spots on the iris, or unexplained discomfort) or initial findings remain inconclusive, request specialized testing or referral to an ocular oncology centre.
While waiting for assessment, avoid self-treatment or delaying medical attention. Symptoms like these should never be dismissed as minor or age-related.
Note: Individuals with known risk factors (fair skin, light-coloured eyes, a history of uveal melanoma, or familial retinoblastoma) should undergo regular eye examinations for early detection.
Is Eye Cancer Common?
Eye cancer is considered rare in comparison to other malignancies, but it can be equally serious depending on the type, location, and stage at diagnosis. Secondary (metastatic) eye cancers, that is, when cancer spreads from another organ such as the breast or lung, are more common than primary eye tumours.
Among adults, uveal (ocular) melanoma is the most frequent type, affecting about 5-6 people per million each year. In children, retinoblastoma occurs in roughly 1 in 15,000-20,000 live births worldwide.
What Age Group is Most at Risk for Eye Cancer?
Eye cancer shows a bimodal age distribution, primarily affecting young children and older adults, depending on the type of malignancy.
In the pediatric population, retinoblastoma is the most common form of eye cancer. It typically develops before the age of five, with most diagnoses occurring in children under two years old. Retinoblastoma may present as either hereditary or non-hereditary, and early detection is associated with high survival rates and the potential for vision preservation.
Among adults, the most prevalent primary intraocular cancer is uveal melanoma, which most frequently occurs in individuals over the age of 50. Risk factors for uveal melanoma include fair skin, light-coloured eyes, and cumulative ultraviolet (UV) radiation exposure. The incidence increases with age and is more common in populations of European ancestry.
Secondary (metastatic) eye cancers, such as those originating from the breast, lung, or prostate, are also more frequently diagnosed in older adults, reflecting the typical age of onset for systemic malignancies.
Can Eye Cancer Cause Blindness?
Yes, eye cancer can lead to partial or complete vision loss if left untreated or detected late.
The risk of blindness is higher with large tumours, delayed diagnosis, or metastatic spread. This is because tumours may damage the retina, optic nerve, or other critical structures and impair sight.
Treatments like surgery, radiation, or chemotherapy can also affect vision, though early, targeted therapy often preserves it.
Can Eye Cancer Spread to the Brain?
Yes, certain types of eye cancer can spread to the brain, though this is relatively uncommon.
Uveal (ocular) melanoma primarily spreads to the liver, but in advanced cases, it may reach the brain or other organs.
Retinoblastoma in children can extend beyond the eye to the optic nerve and central nervous system if untreated.
Resources
- https://my.clevelandclinic.org/health/diseases/retinoblastoma
- https://www.cancer.org/cancer/types/eye-cancer/detection-diagnosis-staging/survival-rates.html
- https://ocularmelanoma.org/basics-of-om
- https://www.ncbi.nlm.nih.gov/books/NBK545276/